Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

CureVac AG: CureVac Raises a Total of USD 640 Million in Private Financing Round

07/21/2020 | 04:50am EST


DGAP-Media / 21.07.2020 / 10:45

CureVac Raises a Total of USD 640 Million in Private Financing Round

- Financing Round includes previously announced investments from German Federal Government and GSK for an amount of USD 514 million

- Additional USD 126 million raised, including participation of Qatar Investment Authority (QIA)

TÜBINGEN, Germany/ BOSTON - July 21, 2020 - CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GSK with USD 171 million as well as additional new equity investments from Qatar Investment Authority (QIA) and a group of existing and new investors with approximately USD 126 million.
 

About CureVac's mRNA technology platform
CureVac's mRNA technology platform has shown potential in the development and production of mRNA based vaccines and therapeutics. CureVac's RNAoptimizer platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.
 

About CureVac
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding, the Bill & Melinda Gates Foundation and the German Kreditanstalt für Wiederaufbau (KfW). CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, GlaxoSmithKline, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, CEPI and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.


CureVac Media Contact
Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

CureVac Investor Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1298
sarah.fakih@curevac.com



End of Media Release


Issuer: CureVac AG
Key word(s): Finance

21.07.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1098189  21.07.2020 

fncls.ssp?fn=show_t_gif&application_id=1098189&application_name=news&site_id=zonebourse

ę EQS 2020
Latest news "Companies"
05:52pINTERPARFUMS : Rochas Girl showered in gold, silver and bronze
PU
05:52pMARCUS & MILLICHAP : Arranges The Sale Of A 10,850-Square Foot Office Building
PU
05:50pREUTERS NEXT-Barbados' Mottley says IMF must help finance the fight against climate change
RE
05:48pBuzzFeed, Inc. Announces Closing Of Business Combination With 890 5th Avenue Partners, Inc. and Acquisition Of Complex Networks
BU
05:47pLGI Homes Reports November 2021 Home Closings
GL
05:46pGreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate
PR
05:42pBitcoin tumbles 5.5% to $53,436
RE
05:42pBANK OF MONTREAL : BMO Financial Group Reports Fourth Quarter and Fiscal 2021 Results - Form 6-K
PU
05:42pNORDSTROM : Morgan Stanley Transcript
PU
05:42pDULUTH : Investor Presentation 3Q 2021 2.1 MB
PU
Latest news "Companies"